Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Hervé Avet-LoiseauJean-Luc Harousseau

Abstract

Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters. A series of 507 patients with newly diagnosed MM who received four cycles of bortezomib-dexamethasone induction therapy before high-dose melphalan were analyzed for both t(4;14) and del(17p). We found that both t(4;14) and del(17p) remain prognostic parameters, even in the context of bortezomib treatment. However, it is important to note that bortezomib significantly improves the prognosis (in terms of both EFS and OS) of patients with t(4;14), compared with patients treated with vincristine, doxorubicin, and dexamethasone induction therapy. In contrast, no improvement was observed for del(17p) patients. Short-term bortezomib induction improves outcome of patients with t(4;14) but not the outcome of patients with del(17p). However, both abnormalities remain prognostic factors predicting both EFS and OS despite bortezomib induction.

References

Sep 25, 2001·Blood·N V SmadjaUNKNOWN Groupe Français de Cytogénétique Hématologique
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Aug 26, 2009·British Journal of Haematology·John D ShaughnessyBart Barlogie

❮ Previous
Next ❯

Citations

Oct 26, 2013·Current Hematologic Malignancy Reports·Jordan Schecter, Suzanne Lentzsch
Mar 5, 2013·International Journal of Hematology·Marta Chesi, P Leif Bergsagel
Feb 5, 2011·Leukemia·M A DimopoulosUNKNOWN European Myeloma Network
Aug 27, 2013·Leukemia·W J ChngUNKNOWN International Myeloma Working Group
Apr 13, 2012·Nature Reviews. Cancer·Gareth J MorganFaith E Davies
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Jun 21, 2012·Carcinogenesis·Kwan Yeung WongChor Sang Chim
Mar 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nikhil C Munshi, Hervé Avet-Loiseau
Oct 2, 2012·The Journal of Clinical Investigation·W Michael Kuehl, P Leif Bergsagel
Dec 14, 2011·Hematology·Marta Chesi, P Leif Bergsagel
Aug 23, 2012·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C C G LinardiP Dorlhiac-Llacer
Jun 21, 2011·Haematologica·Damien Roos-WeilUNKNOWN Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Dec 4, 2012·Mediterranean Journal of Hematology and Infectious Diseases·P TosiG Visani
Jan 1, 2014·Acta Biochimica Et Biophysica Sinica·Xiubao ChangA Keith Stewart
Apr 6, 2013·Immunotherapy·Alessandra RomanoFrancesco Di Raimondo
May 8, 2014·Advances in Hematology·Steven M PrideauxTimothy J Chevassut
May 9, 2014·Epigenomics·Charlotte PawlynGareth J Morgan
Apr 5, 2014·Journal of the National Cancer Institute·Sascha A TuchmanJerome W Yates
Oct 9, 2014·Bone Marrow Research·Steven M PrideauxTimothy J Chevassut
Sep 13, 2014·Hematology/oncology Clinics of North America·Niels W C J van de Donk, Pieter Sonneveld
Aug 10, 2011·Leukemia & Lymphoma·Allan JiangHong Chang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.